Better Therapeutics Stock Fundamentals
| BTTXDelisted Stock | USD 0.73 0.04 5.19% |
Better Therapeutics fundamentals help investors to digest information that contributes to Better Therapeutics' financial success or failures. It also enables traders to predict the movement of Better OTC Stock. The fundamental analysis module provides a way to measure Better Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Better Therapeutics otc stock.
Better |
Better Therapeutics OTC Stock Shares Outstanding Analysis
Better Therapeutics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Better Therapeutics Shares Outstanding | 54.52 M |
Most of Better Therapeutics' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Better Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
CompetitionBased on the latest financial disclosure, Better Therapeutics has 54.52 M of shares currently outstending. This is 69.8% lower than that of the Biotechnology sector and 48.98% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 90.47% higher than that of the company.
Better Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Better Therapeutics's current stock value. Our valuation model uses many indicators to compare Better Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Better Therapeutics competition to find correlations between indicators driving Better Therapeutics's intrinsic value. More Info.Better Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Better Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Better Therapeutics' OTC Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Better Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Better Therapeutics' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Better Therapeutics could also be used in its relative valuation, which is a method of valuing Better Therapeutics by comparing valuation metrics of similar companies.Better Therapeutics is currently under evaluation in shares outstanding category among its peers.
Better Fundamentals
| Return On Equity | -10.22 | ||||
| Return On Asset | -0.95 | ||||
| Current Valuation | 8.83 M | ||||
| Shares Outstanding | 54.52 M | ||||
| Shares Owned By Insiders | 53.41 % | ||||
| Shares Owned By Institutions | 2.94 % | ||||
| Number Of Shares Shorted | 2.13 M | ||||
| Price To Book | 2.29 X | ||||
| Price To Sales | 49,559 X | ||||
| Gross Profit | (674 K) | ||||
| EBITDA | (29.18 M) | ||||
| Net Income | (31.57 M) | ||||
| Cash And Equivalents | 29.68 M | ||||
| Cash Per Share | 1.25 X | ||||
| Total Debt | 14.88 M | ||||
| Debt To Equity | 0.81 % | ||||
| Current Ratio | 5.23 X | ||||
| Book Value Per Share | (0.24) X | ||||
| Cash Flow From Operations | (26.08 M) | ||||
| Short Ratio | 0.94 X | ||||
| Earnings Per Share | (1.10) X | ||||
| Target Price | 5.25 | ||||
| Number Of Employees | 54 | ||||
| Beta | 2.35 | ||||
| Market Capitalization | 1.12 M | ||||
| Total Asset | 22.94 M | ||||
| Retained Earnings | (111.5 M) | ||||
| Working Capital | 4.95 M | ||||
| Z Score | -10.7 | ||||
| Net Asset | 22.94 M |
About Better Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Better Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Better Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Better Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Better Therapeutics, Inc. engages in developing software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California. Better Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 44 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Other Consideration for investing in Better OTC Stock
If you are still planning to invest in Better Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Better Therapeutics' history and understand the potential risks before investing.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Stocks Directory Find actively traded stocks across global markets | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |